Novartis taps smartpatient for app to support wet AMD patients
pharmaphorum
NOVEMBER 23, 2020
German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness. Novartis earned $2 billion from Lucentis last year, while Roche – which sells it in the US – made $1.8 billion from the drug.
98 
Let's personalize your content